Loading…
Loading…
Compass Wealth Management LLC reduced its holdings in shares of Danaher Corporation (NYSE: DHR) by 9.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,242 shares of the conglomerate's stock after selling 4,464 shares during the period. Danaher comprises approximately 1.9%
Cantor Fitzgerald Investment Advisors L.P. bought a new stake in shares of Danaher Corporation (NYSE: DHR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,500 shares of the conglomerate's stock, valued at approximately $997,000. Several other hedge funds and other institutional investors
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.
It beat analyst estimates for both revenue and profitability. Its full-year earnings guidance also topped the pundit consensus.
Danaher Corporation ( DHR ) Q3 2026 Earnings Call October 21, 2026 8:00 AM EDT Company Participants Rachel Vatnsdal Olson - Vice President of Investor Relations Julie Montgomery - President, CEO & Director Matthew Gugino - Executive VP & CFO Conference Call Participants Doug Schenkel Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Scott Davis - Melius Research LLC Casey Woodring - JPMorgan Chase & Co, Research Division Elizabeth Koslosky - Goldman Sachs Group, Inc., Research Division Presentation Operator My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2026 Earnings Results Conference Call.
Danaher raised full-year earnings per share guidance to $8.57 to $8.62. Biotechnology orders grew mid-teens during the third quarter.
Revenue: Q3 2026 sales of $6.6 billion.Core Revenue Growth: Up 3% overall; up 5.5% excluding respiratory revenue (100 bps acceleration from Q2).Respiratory Reve